Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: Revisiting the Weber effect

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 9, 2008, Pages 882-889

  McAdams, Mara A ^a   Governale, Laura A ^a   Swartz, Lynette ^a   Hammad, Tarek A ^a   Pan, Gerald J Dal ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse event reporting; Angiotensin II receptor blockers; Food and drug administration; Weber effect

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

ARTICLE; CONSUMER; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; SELF REPORT; TREND STUDY; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DRUG APPROVAL; HUMANS; LOSARTAN; TETRAZOLES; TIME FACTORS; UNITED STATES; VALINE;

EID: 52949152357     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1633     Document Type: Article

References (10)

1. Ahmad SR, Goetsch RA, Marks NS. Spontaneous reporting in the United States. In Pharmacoepidemiology, (4th edn), Strom BL (ed.). John Wiley & Sons: New York, NY, 2005; 135-159.
2. Title 21 of the Code of Federal Regulations, Subpart 314.80. Additionally, 21 CFR 310.305 and 21 CFR 314.98.
3. Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In Advances in Inflammation Research, Rainsford KD, Velo GP (eds). Raven Press: New York, NY, 1984; 1-7.
4. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 2001; 24: 233-237.
5. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004; 24; 743-749. DOI: 10.1592/phco.24.9.743.36068
6. Hartnell NR, Wilson JP, Patel NC, et al. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother 2003; 37: 1387-1391. DOI: 10.1345/aph.1C522
7. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33.
8. Title 21 of the Code of Federal Regulations, Subpart 314.80.
9. Title 21 of the Code of Federal Regulations, Subpart 314.90.
10. Food and Drug Administration. Center for Drug Evaluation and Research, Office of Drug Safety. Annual Report FY 2004. http://www.fda.gov/cder/ Offices/ODS/AnnRep2004/default.htm#_Toc66679476 (Accessed 8 August 2007).